Pulmonary and Critical Care

About the Conference

We are pleased to welcome participants from across the globe to the 12th Annual Congress on Pulmonary and Critical Care, scheduled for April 23-24, 2026, in Paris, France. This year’s Pulmonary Meet 2026 will spotlight the theme “Transforming Respiratory Health: Breakthroughs in Diagnosis, Treatment & Critical Care.”

The 2026 conference aims to foster the exchange of innovative ideas and emerging research by bringing together leading pulmonologists, critical care specialists, researchers, industry professionals, decision-makers, and global healthcare experts. Pulmonary Meet 2026 is set to be a premier international event, highlighting impactful scientific developments in respiratory and critical care medicine.

Pulmonary Meet 2026 invites pulmonologists, respiratory care practitioners, and experts in respiratory medicine worldwide to explore the latest advancements in screening, diagnosing, treating, and managing respiratory diseases. The scientific program will include comprehensive sessions on COPD, asthma, allergies, cystic fibrosis, pneumonia, tuberculosis, emphysema, lung cancer, complex chest infections, pulmonary fibrosis, sleep apnea, interstitial lung disease, lung nodules, chronic cough, influenza, mycobacterial infections, pediatric pulmonary conditions, bronchiectasis, and critical care. The event will also cover multidisciplinary approaches aimed at enhancing cardiopulmonary function, wellness, and patient outcomes.

Pulmonary Meet 2026 will feature distinguished keynote lectures, insightful research presentations through oral and poster sessions, interactive workshops, exhibitor showcases, and dedicated networking sessions. Attendees will also have opportunities for one-on-one meetings and collaborative discussions with global professionals in the field.

Why Attend?

This congress offers a valuable platform to engage with world-renowned experts in pulmonology and critical care. It provides an exceptional opportunity to connect with professionals from universities, research institutions, hospitals, and clinical centers. Participants can present research, exchange knowledge, explore collaborations, meet potential speakers, and showcase innovative products and technologies. With cutting-edge updates, breakthrough techniques, and impactful discussions, Pulmonary Meet 2026 aims to drive professional growth and inspire new solutions that elevate respiratory medicine worldwide.

Target Audience:

• Pulmonologists

• Critical Care Professionals

• Pediatric Pulmonologists

• Pulmonology Professors

• Pulmonology Nurses

• Critical Care Hygienists

• Respiratory Therapists

• Healthcare Professionals

• Scientists & Researchers

• Academic Professionals

• Medical Students

• Medical Device Manufacturers

Sessions & Tracks

Track 01 – Pulmonology

Pulmonology, or respiratory medicine, focuses on diseases of the lungs, airways, and respiratory muscles. Pulmonologists diagnose and treat conditions that impair breathing and lung function. Common disorders include asthma, COPD, lung cancer, pneumonia, and tuberculosis. With growing clinical innovations, pulmonology continues to advance through improved diagnostics, multidisciplinary care, and personalized treatment strategies.

Track 02 – Lung Cancer

Lung cancer remains a major global health challenge and a leading cause of cancer-related deaths. Research in 2026 emphasizes precision oncology, early detection technologies, biomarker-driven therapies, liquid biopsies, targeted treatments, and advanced immunotherapies. These developments are transforming survival outcomes and enabling highly individualized cancer care.

Track 03 – Respiratory Disorders

Respiratory disorders include a wide range of acute and chronic conditions affecting lung function. The field is evolving with breakthroughs in molecular diagnostics, digital respiratory monitoring, AI tools, and environmental health-focused research. Multidisciplinary management remains essential for improved patient care and long-term outcomes.

Track 04 – Chronic Obstructive Pulmonary Disease (COPD)

COPD, encompassing chronic bronchitis and emphysema, is marked by progressive airflow limitation. Advances for 2026 include next-generation inhalers, biologic therapies, endobronchial interventions, enhanced pulmonary rehabilitation, and personalized medicine approaches. Early detection and risk-factor modification remain critical for improving prognosis.

Track 05 – Respiratory Tract Infections

Respiratory tract infections (RTIs) range from mild viral illnesses to severe bacterial pneumonia. Enhanced diagnostic tools, rapid molecular testing, antiviral innovations, and lessons from the COVID-19 era continue to improve prevention and management. Global collaborative research drives progress in preparedness and response strategies.

Track 06 – Pulmonary Rehabilitation

Pulmonary rehabilitation improves physical conditioning, symptom control, and emotional well-being in chronic respiratory disease. Modern programs integrate personalized training, tele-rehabilitation, digital monitoring, and behavior-change strategies, significantly enhancing quality of life and long-term functional capacity.

Track 07 – Pleural Diseases

Pleural diseases affect the membranes surrounding the lungs and can cause significant respiratory compromise. Advances in 2026 include minimally invasive diagnostic techniques, thoracoscopy, pleural ultrasound, and biomarker-based differentiation of pleural effusions. Tailored therapies and interdisciplinary care are improving patient outcomes.

Track 08 – Lung Transplantation

Lung transplantation offers life-saving treatment for advanced lung diseases such as COPD, pulmonary fibrosis, cystic fibrosis, and severe pulmonary hypertension. Ongoing innovations in surgical methods, organ preservation, donor-recipient matching, and immunosuppression have improved survival and quality of life. Transplant approaches include single-lung, double-lung, and heart-lung procedures.

Track 09 – Tuberculosis

Tuberculosis (TB) continues to pose a global public health challenge. 2026 focuses on rapid diagnostics, shorter treatment regimens, drug-resistance management, and improved vaccines. Understanding the clinical spectrum—from latent TB to active disease—remains essential for early detection and control.

Track 10 – Cystic Fibrosis

Cystic fibrosis is a genetic disorder affecting the respiratory and digestive systems due to CFTR gene mutations. Transformative therapies such as CFTR modulators and ongoing gene-therapy research are significantly improving life expectancy. The 2026 track highlights innovations in precision medicine, infection control, and multidisciplinary care.

Track 11 – Prevention and Control of Respiratory Diseases

Effective prevention strategies include vaccination (influenza, pneumococcal, BCG), smoking cessation programs, environmental protection, occupational safety, and strong infection-control practices. Public health initiatives, early detection, and behavioral changes are crucial for reducing the global respiratory disease burden.

Track 12 – Chronic Bronchitis

Chronic bronchitis, a major component of COPD, is defined by long-term airway inflammation and persistent mucus-producing cough. Advances in 2026 emphasize early identification, combination therapies, pulmonary rehabilitation, smoking cessation support, and improved disease-management models.

Track 13 – Asthma

Asthma involves chronic airway inflammation leading to wheezing, breathlessness, chest tightness, and coughing. Modern asthma care integrates biologic therapies, personalized inhaler regimens, environmental control, and digital monitoring tools for optimal disease control and patient empowerment.

Track 14 – Interstitial Lung Disease (ILD)

ILD includes a diverse group of disorders characterized by lung tissue inflammation and fibrosis. Idiopathic Pulmonary Fibrosis, NSIP, DIP, connective-tissue disease–related ILD, occupational ILD, and drug-induced ILD remain central research areas. Advances in antifibrotic therapies, imaging techniques, and multidisciplinary care are improving diagnostic accuracy and management.

Track 15 – Pulmonary Hypertension

Pulmonary hypertension is elevated blood pressure in the pulmonary arteries, leading to strain on the heart and impaired oxygenation. In 2026, research focuses on novel vasodilators, targeted therapies for PAH, improved imaging, and early detection strategies. Associated conditions include autoimmune disorders, congenital heart disease, and pulmonary embolism.

Track 16 – Infectious Respiratory Diseases

Infectious respiratory diseases—including common colds, sinusitis, bronchitis, pneumonia, tuberculosis, influenza, COVID-19, and RSV—remain major global concerns. The 2026 focus includes pathogen surveillance, antimicrobial stewardship, vaccine development, and emerging therapeutic modalities.

Track 17 – Sleep-Related Respiratory Disorders

Sleep-related respiratory disorders include obstructive and central sleep apnea, complex sleep apnea, sleep-related hypoventilation, and movement-related sleep disturbances. Treatments range from CPAP, BiPAP, and ASV devices to lifestyle modification, oral appliances, and surgical interventions. Early diagnosis is key to preventing cardiovascular and metabolic consequences.

Track 18 – Emphysema

Emphysema involves irreversible destruction of alveoli leading to reduced gas exchange. Cigarette smoking remains the primary cause, with environmental pollutants and genetic factors like alpha-1 antitrypsin deficiency also contributing. Cutting-edge research explores lung-volume reduction techniques, biologics, novel inhalation therapies, and genetic approaches.

Track 19 – Lung Problems

This track covers a broad spectrum of respiratory issues, including infections, asthma, COPD, ILD, pulmonary hypertension, and structural lung disorders. Emphasis for 2026 is on integrated diagnostics, precision therapy, digital lung-health monitoring, and holistic care approaches that address both acute and chronic conditions.

Track 20 – Pulmonary Vascular Disease

Pulmonary vascular disease includes pulmonary hypertension, pulmonary embolism, arteriovenous malformations, vasculitis, and rare capillary disorders. New developments include advanced imaging, anticoagulant therapies, targeted vasodilators, minimally invasive procedures, and personalized treatment pathways to reduce morbidity and mortality.

Market Analysis

The pulmonary/respiratory drug delivery market, valued at USD 53,018.64 million in 2021, is projected to expand to USD 87,745.62 million by 2029, registering a CAGR of 6.5% from 2022 to 2029. As we move toward 2026, COPD remains the largest and fastest-growing application segment, propelled by favorable reimbursement frameworks, a rising global patient pool, and persistent high mortality associated with the disease.

The latest market assessment—compiled by the Data Bridge Market Research team—provides an in-depth evaluation of key industry dynamics including expert analyses, demographic patterns, emerging pipeline products, pricing shifts, and regulatory landscapes. Pulmonary and respiratory drug delivery technologies continue to be preferred due to their non-invasive nature, extensive absorption surface area, strong vascular supply, and high permeability, making them highly effective for targeted respiratory therapies.

The 2026 market outlook includes detailed segment-based insights across product type, canister design, application, distribution channel, and end user categories. The analysis covers major global regions:

• North America (U.S., Canada, Mexico)

• Europe (Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe)

• Asia-Pacific (APAC) (China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of APAC)

• Middle East & Africa (MEA) (Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of MEA)

• South America (Brazil, Argentina, Rest of South America)

North America continues to lead the global market due to the strong presence of major industry players, increasing adoption of Pulmonary Drug Delivery Systems (PDDS), rising disposable income, and the high prevalence of respiratory conditions such as asthma and COPD.

This robust market growth trajectory underscores the expanding role of innovative drug delivery platforms in shaping the future of respiratory care worldwide